Pfizer CEO Albert Bourla says that his company and other large pharmaceutical firms are looking at working with the Trump administration to make more of their medicines available at lower costs to consumers.
In a conference call with investors on Tuesday to discuss second-quarter earnings, Bourla said, “We have serious discussions in the industry,” according to BioPharma Dive.